NDC 63539-502

XELJANZ XR

Tofacitinib

XELJANZ XR is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by U.s. Pharmaceuticals. The primary component is Tofacitinib Citrate.

Product ID63539-502_11ae0c37-f8b9-44bf-b4a7-aef76dd348e3
NDC63539-502
Product TypeHuman Prescription Drug
Proprietary NameXELJANZ XR
Generic NameTofacitinib
Dosage FormTablet, Extended Release
Route of AdministrationORAL
Marketing Start Date2020-01-21
Marketing CategoryNDA / NDA
Application NumberNDA208246
Labeler NameU.S. Pharmaceuticals
Substance NameTOFACITINIB CITRATE
Active Ingredient Strength22 mg/1
Pharm ClassesJanus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 63539-502-30

30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63539-502-30)
Marketing Start Date2020-01-21
NDC Exclude FlagN
Sample Package?Y

NDC SPL Data Element Entries

NDC 63539-502-30 [63539050230]

XELJANZ XR TABLET, EXTENDED RELEASE
Marketing CategoryNDA
Application NumberNDA208246
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2020-01-21

Drug Details

Active Ingredients

IngredientStrength
TOFACITINIB CITRATE22 mg/1

Pharmacological Class

  • Janus Kinase Inhibitor [EPC]
  • Janus Kinase Inhibitors [MoA]

NDC Crossover Matching brand name "XELJANZ XR" or generic name "Tofacitinib"

NDCBrand NameGeneric Name
63539-501XELJANZ XRXELJANZ XR
63539-502XELJANZ XRXELJANZ XR
0069-0501XELJANZtofacitinib
0069-0502XELJANZtofacitinib
0069-1001XELJANZtofacitinib
0069-1002XELJANZtofacitinib

Trademark Results [XELJANZ]

Mark Image

Registration | Serial
Company
Trademark
Application Date
XELJANZ
XELJANZ
86126490 4563705 Live/Registered
Pfizer Inc.
2013-11-22
XELJANZ
XELJANZ
85678862 not registered Dead/Abandoned
Pfizer Inc.
2012-07-17
XELJANZ
XELJANZ
77688128 4099367 Live/Registered
Pfizer Inc.
2009-03-11

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.